These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30429093)

  • 1. [Patients in the IDEAL cohort: A snapshot of severe asthma in France].
    Taillé C; Pison C; Nocent C; Devouassoux G; Prud'homme A; Gruber A; Gunsoy N; Albers F
    Rev Mal Respir; 2019 Feb; 36(2):179-190. PubMed ID: 30429093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
    Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
    Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
    Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial.
    Cornelius V; Babalis D; Carroll WD; Cunningham S; Fleming L; Gaillard E; Gupta A; Janani L; Kennington E; Murray C; Nagakumar P; Roberts G; Seddon P; Sinha I; Streatfield C; Weir E; Saglani S
    BMJ Open; 2024 Aug; 14(8):e090749. PubMed ID: 39174059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
    Nopsopon T; Barrett NA; Phipatanakul W; Laidlaw TM; Weiss ST; Akenroye A
    Allergy; 2024 May; 79(5):1195-1207. PubMed ID: 38164813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P; McCormack K; Malka-Rais J; Spahn JD
    J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.
    Schreiber J; Schwab Sauerbeck I; Mailänder C
    Adv Ther; 2020 Jan; 37(1):353-363. PubMed ID: 31741282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study.
    Cakmak ME; Öztop N; Yeğit OO
    Int Arch Allergy Immunol; 2024; 185(2):158-166. PubMed ID: 37992693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
    Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
    Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
    Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
    Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.